Robert C. Goeltz II Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert C. Goeltz II.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Robert C. Goeltz II. Robert C. Goeltz II is a Chief Financial Officer in Unity Biotechnology, Inc. ($UBX) and a Chief Financial Officer in CytomX Therapeutics, Inc. ($CTMX) and a Chief Financial Officer in Arcus Biosciences, Inc. ($RCUS).
Address: 343 OYSTER POINT BLVD. SUITE 100 SOUTH SAN FRANCISCO 94080 CA
Companies in which Robert C. Goeltz II is an Insider
Arcus Biosciences, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Robert C. Goeltz II: Chief Financial Officer
Holdings: 17,500 shares
Latest Transaction: Jan 20 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
CytomX Therapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Robert C. Goeltz II: Chief Financial Officer
Holdings: 22,769 shares
Current Value: $261,844
Latest Transaction: May 16 2017
$CTMX Market Capitalization: $410.61M
$CTMX Previous Close: $11.50
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Unity Biotechnology, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Robert C. Goeltz II: Chief Financial Officer
Holdings: 161,027 shares
Latest Transaction: Jun 24 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Robert C. Goeltz II
Sentiment: All, RCUS, CTMX, UBX
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 20 2021 | RCUS | Arcus Biosciences, ... | Goeltz II Robert C. | Chief Financial Off ... | Option Exercise | A | 36.73 | 75,000 | 2,754,750 | 75,000 | |
| Jan 20 2021 | RCUS | Arcus Biosciences, ... | Goeltz II Robert C. | Chief Financial Off ... | Grant | A | 0.00 | 12,500 | 0 | 17,500 | 5 K to 17.5 K (+250.00 %) |
| Sep 09 2020 | RCUS | Arcus Biosciences, ... | Goeltz II Robert C. | Chief Financial Off ... | Buy | P | 21.57 | 5,000 | 107,849 | 5,000 | 0 to 5 K |
| Sep 09 2020 | RCUS | Arcus Biosciences, ... | Goeltz II Robert C. | Chief Financial Off ... | Buy | P | 21.57 | 5,000 | 107,849 | 5,000 | 0 to 5 K |
| Aug 04 2020 | RCUS | Arcus Biosciences, ... | Goeltz II Robert C. | Chief Financial Off ... | Option Exercise | A | 21.06 | 250,000 | 5,265,000 | 250,000 | |
| Jun 24 2020 | UBX | Unity Biotechnolog ... | Goeltz II Robert C. | Chief Financial Off ... | Payment of Exercise | F | 9.67 | 2,483 | 24,011 | 161,027 | 163.5 K to 161 K (-1.52 %) |
| Apr 01 2020 | UBX | Unity Biotechnolog ... | Goeltz II Robert C. | Chief Financial Off ... | Option Exercise | A | 5.95 | 118,188 | 703,219 | 118,188 |